Advertisement
ARCT vs VCYT
Which Stock Would AI Choose? Arcturus Therapeutics (ARCT) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- Arcturus Therapeutics (ARCT) is a clinical-stage mRNA medicines company trading near its 52-week lows amid declining revenue and a strategic pivot away from COVID-19 vaccines toward rare disease therapeutics.
- Veracyte (VCYT) is a profitable cancer diagnostics company delivering double-digit revenue growth, expanding testing volumes, and generating robust operating cash flow from its Decipher and Afirma testing franchises.
- ARCT trades at approximately $5.76 with a market capitalization under $165 million, while VCYT trades near $55.65 with a market cap exceeding $4.4 billion — reflecting vastly different levels of investor confidence and business maturity.
- ARCT carries high clinical-upside potential from its cystic fibrosis and OTC deficiency (ornithine transcarbamylase deficiency) programs but remains unprofitable with contracting revenue; VCYT offers consistent execution, positive GAAP (Generally Accepted Accounting Principles) net income, and strong adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margins above 27%.
- The two companies operate in entirely different subsectors of healthcare — biotechnology versus diagnostics — making this comparison a study in risk tolerance, growth stage, and business model stability.
Introduction
Investors evaluating healthcare stocks often face a fundamental choice: back a pre-revenue or early-commercial biotech with transformational science but uncertain outcomes, or invest in an established diagnostic platform with recurring revenue and proven market adoption. ARCT and VCYT represent opposite ends of this spectrum. Arcturus Therapeutics is a San Diego-based mRNA medicines company focused on rare respiratory and liver diseases, while Veracyte is a South San Francisco-based cancer diagnostics leader with a growing portfolio of genomic tests. This stock comparison examines how these two names stack up across recent performance, business fundamentals, and market positioning — offering traders and long-term investors a clear, data-driven picture of where each stands in the current market environment.
ARCT Overview and Recent Performance
Arcturus Therapeutics Holdings (ARCT) develops messenger RNA (mRNA) therapeutics and vaccines using its proprietary STARR® self-amplifying mRNA platform and LUNAR® lipid-mediated delivery technology. The company's pipeline is anchored by two rare disease programs: ARCT-032 for cystic fibrosis (CF) and ARCT-810 for OTC deficiency, alongside partnered vaccine programs with CSL Seqirus and Japan's Meiji Seika Pharma for its KOSTAIVE® COVID-19 vaccine.
In recent months, ARCT shares have experienced significant downward pressure, trading near $5.76 — a decline of over 61% from its 52-week highs and near the bottom of its 52-week range. The company's financial performance reflects a difficult transition: full-year 2025 revenue fell to approximately $82 million, down from $152.3 million in 2024, driven primarily by reduced collaboration revenue from CSL as COVID-19 vaccine programs wind down. The company reported a net loss of roughly $65.8 million for fiscal 2025. Despite operating expense reductions — R&D (Research and Development) spending declined significantly year-over-year — the top-line contraction has weighed heavily on sentiment.
On the clinical front, ARCT has achieved notable milestones. The ARCT-032 Phase 2 program showed encouraging interim data with mucus plug reduction in Class I CF patients, and a 12-week open-label Phase 2 study began enrollment in early 2026. For ARCT-810, Type C meetings with the FDA have provided regulatory clarity toward a pediatric pivotal development path. The company maintains a cash position of approximately $213.4 million as of Q1 2026, with management guiding a cash runway extending beyond Q2 2028. Still, the stock's high beta of 2.36 reflects elevated volatility that has kept risk-averse investors on the sidelines.
VCYT Overview and Recent Performance
Veracyte (VCYT) is a global cancer diagnostics company whose Veracyte Diagnostics Platform delivers high-performing genomic tests — most notably Decipher Prostate and Afirma — that help clinicians guide treatment decisions at critical moments in cancer care. The company serves over 800,000 patients cumulatively and generates the majority of its revenue from testing services reimbursed by payers, underpinned by a growing body of clinical evidence and guideline inclusion.
In recent quarters, VCYT has demonstrated consistent commercial execution. Full-year 2025 total revenue reached $517.1 million, a 16% increase year-over-year, with testing revenue climbing 18% to $493.2 million. Decipher volume grew 27% to approximately 102,000 tests, while Afirma volume rose 11%. The company achieved GAAP net income of $66.4 million for 2025 and delivered adjusted EBITDA of $142.5 million, representing a 27.6% margin — a significant improvement over the prior year. Cash flow from operations reached $136.3 million, and the company ended 2025 with $412.9 million in cash and short-term investments.
Looking ahead, Veracyte has guided for 2026 total revenue of $570 million to $582 million, reflecting 10–13% growth, with testing revenue expected to grow 14–16%. Upcoming catalysts include the U.S. launch of the Prosigna breast cancer test as an LDT (Laboratory Developed Test) and the TrueMRD platform for minimal residual disease monitoring. With a forward P/E (Price-to-Earnings) ratio of approximately 32 and a market cap near $4.4 billion, VCYT trades at a premium that reflects investor confidence in its durable growth trajectory, though recent insider selling activity has attracted some attention from market observers.
Trending AI Robots
For investors seeking a data-driven edge in navigating complex stock comparisons like this one, Tickeron's Trending AI Robots page offers a curated selection of top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading bots that execute across thousands of tickers, each with distinct trading styles, strategies, timeframes, and risk parameters. However, only those robots demonstrating the strongest alignment with current market conditions earn a place in the Trending AI Robots section. These bots are designed to adapt to shifting volatility, momentum, and trend regimes — incorporating statistical track records that include metrics such as annualized return, win rate, trade frequency, and maximum drawdown. Whether an investor is focused on short-term swing trading or longer-term positional strategies, this curated hub provides an accessible starting point for exploring AI-driven trading. Discover which bots are currently trending at Trending AI Robots.
Head-to-Head Comparison
Placing ARCT and VCYT side by side highlights stark contrasts across nearly every relevant investment dimension.
Business Model and Revenue Visibility: VCYT operates a high-volume, reimbursed diagnostic testing model with recurring revenue, strong gross margins (non-GAAP gross margin of 72.9% in FY2025), and clear growth visibility from an expanding test menu. ARCT, by contrast, relies on collaboration and milestone payments from pharmaceutical partners whose contribution has been shrinking, with no near-term path to self-sustaining commercial revenue from its rare disease pipeline.
Profitability and Cash Flow: VCYT is solidly profitable on a GAAP basis, generating $136.3 million in operating cash flow in FY2025. ARCT remains deeply unprofitable with a net loss of $65.8 million and negative operating cash flow, though its cash runway provides a multi-year buffer for clinical development.
Growth Trajectory: VCYT has delivered consistent double-digit revenue growth driven by increasing test volumes and deeper market penetration. ARCT is contracting on the top line as legacy COVID-19 programs fade, with future growth entirely dependent on clinical trial outcomes that remain years from potential commercialization.
Risk Profile: ARCT carries binary clinical risk — positive Phase 2 CF or OTC data could dramatically change its valuation, while failure would severely impair the investment case. VCYT faces competitive and reimbursement risk but operates in a more predictable regulatory and commercial environment. Both stocks carry above-average beta, but ARCT's beta of 2.36 is substantially higher than VCYT's 1.93.
Market Sentiment and Institutional Backing: Institutional ownership for both stocks is high — approximately 94% for ARCT and over 80% for VCYT. However, analyst sentiment diverges meaningfully: VCYT commands a consensus Buy rating with relatively tight price target dispersion, while ARCT's analyst targets range from $9 to $54 — a spread that underscores deep uncertainty about the company's future.
Tickeron AI Verdict
Based on observable trend data and relative positioning, Tickeron's AI-driven models would likely favor VCYT in the current market environment. The rationale rests on several objective factors: VCYT exhibits stronger trend consistency with rising revenue, expanding margins, and positive earnings momentum, while ARCT continues to trade under the weight of declining revenue and negative earnings against a backdrop of high clinical uncertainty. VCYT's diversified test portfolio, durable reimbursement framework, and tangible near-term catalysts such as the Prosigna and TrueMRD launches provide more identifiable drivers of value realization. That said, ARCT cannot be dismissed — its CF and OTC programs address genuine unmet medical needs, and any statistically meaningful clinical data readout could trigger significant price re-rating. An AI framework would likely acknowledge VCYT's superior stability and trend quality while flagging ARCT as a higher-risk, higher-reward asymmetric opportunity dependent on binary clinical catalysts. In probabilistic terms, VCYT currently presents the more consistent risk-adjusted profile for trend-following strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and VCYT is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARCT’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).
- ARCT’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARCT’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 4 bullish TA indicator(s).
- ARCT’s TA Score: 4 bullish, 3 bearish.
- VCYT’s TA Score: 4 bullish, 4 bearish.
Price Growth
ARCT (@Biotechnology) experienced а +2.25% price change this week, while VCYT (@Medical Specialties) price change was +3.28% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.06%. For the same industry, the average monthly price growth was -6.89%, and the average quarterly price growth was +2790.38%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.48%. For the same industry, the average monthly price growth was -3.65%, and the average quarterly price growth was +7.38%.
Reported Earning Dates
ARCT is expected to report earnings on Aug 10, 2026.
VCYT is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Biotechnology (+1.06% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+0.48% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ARCT | VCYT | ARCT / VCYT | |
| Capitalization | 168M | 4.78B | 4% |
| EBITDA | -75M | 112M | -67% |
| Gain YTD | -3.426 | 41.995 | -8% |
| P/E Ratio | N/A | 55.43 | - |
| Revenue | 42.4M | 542M | 8% |
| Total Cash | 211M | 439M | 48% |
| Total Debt | 24M | 39.3M | 61% |
ARCT | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 59 Fair valued | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 69 | |
SMR RATING 1..100 | 99 | 81 | |
PRICE GROWTH RATING 1..100 | 82 | 36 | |
P/E GROWTH RATING 1..100 | 100 | 54 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARCT's Valuation (59) in the Pharmaceuticals Major industry is in the same range as VCYT (62) in the Biotechnology industry. This means that ARCT’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's Profit vs Risk Rating (69) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that VCYT’s stock grew similarly to ARCT’s over the last 12 months.
VCYT's SMR Rating (81) in the Biotechnology industry is in the same range as ARCT (99) in the Pharmaceuticals Major industry. This means that VCYT’s stock grew similarly to ARCT’s over the last 12 months.
VCYT's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for ARCT (82) in the Pharmaceuticals Major industry. This means that VCYT’s stock grew somewhat faster than ARCT’s over the last 12 months.
VCYT's P/E Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that VCYT’s stock grew somewhat faster than ARCT’s over the last 12 months.
| ARCT | VCYT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| Advances ODDS (%) | 2 days ago 80% | 2 days ago 73% |
| Declines ODDS (%) | 8 days ago 87% | 5 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 89% | 5 days ago 77% |
| Aroon ODDS (%) | N/A | 2 days ago 74% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EWX | 66.85 | 0.69 | +1.04% |
| State Street® SPDR® S&P® EM Sm Cp ETF | |||
| IWN | 221.79 | 0.19 | +0.09% |
| iShares Russell 2000 Value ETF | |||
| JHI | 13.07 | 0.01 | +0.08% |
| John Hancock Investors Trust Capital Stock | |||
| MMMA | 25.16 | 0.01 | +0.02% |
| NYLI MacKay Muni Allocation ETF | |||
| JRE | 28.24 | -0.55 | -1.92% |
| Janus Henderson US Real Estate ETF | |||
ARCT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.
| Ticker / NAME | Correlation To ARCT | 1D Price Change % | ||
|---|---|---|---|---|
| ARCT | 100% | +2.25% | ||
| ALEC - ARCT | 56% Loosely correlated | +6.58% | ||
| AXON - ARCT | 49% Loosely correlated | -1.11% | ||
| EDIT - ARCT | 44% Loosely correlated | +3.46% | ||
| VCYT - ARCT | 42% Loosely correlated | +7.31% | ||
| QSI - ARCT | 40% Loosely correlated | +2.52% | ||
More | ||||
VCYT and
Correlation & Price change
A.I.dvisor indicates that over the last year, VCYT has been closely correlated with NTLA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if VCYT jumps, then NTLA could also see price increases.
| Ticker / NAME | Correlation To VCYT | 1D Price Change % | ||
|---|---|---|---|---|
| VCYT | 100% | +7.31% | ||
| NTLA - VCYT | 69% Closely correlated | +2.69% | ||
| VCEL - VCYT | 60% Loosely correlated | +2.12% | ||
| AXON - VCYT | 58% Loosely correlated | -1.11% | ||
| DNA - VCYT | 57% Loosely correlated | +6.17% | ||
| ABCL - VCYT | 55% Loosely correlated | +5.57% | ||
More | ||||